Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

Fig. 1

Improvement in BCVA and reduction in retinal thickness at 1, 2 and 3 years after treatment with FAc implant. Graph (a) showing mean values for ETDRS letters gained, mean (SD) central retinal thickness (CRT) and peak macular thickness as measured by SD-OCT. Significance at each time-point was tested against baseline (b)

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us